PT-141 Research for Low Libido
An evidence-based overview of research examining PT-141 in the context of low libido. This page synthesizes findings from peer-reviewed literature.
Research Summary
PT-141 addresses low libido through melanocortin-4 receptor activation in brain areas involved in sexual motivation. Unlike hormonal treatments, it works through central neural pathways. The RECONNECT trials demonstrated efficacy in women with acquired, generalized HSDD. Improvements were seen in sexual desire, satisfying sexual events, and sexual distress scores. As an on-demand treatment (taken before anticipated activity), PT-141 offers a different approach than daily medications. The nausea side effect limits tolerability for some patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Low Libido
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. PT-141 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.